Insider Selling: Firefly Neuroscience (NASDAQ:AIFF) Major Shareholder Sells $114,841.80 in Stock

Firefly Neuroscience, Inc. (NASDAQ:AIFF) major shareholder Windsor Private Capital Lp sold 45,036 shares of the business’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $2.55, for a total transaction of $114,841.80. Following the completion of the transaction, the insider owned 1,367,526 shares in the company, valued at $3,487,191.30. The trade was a 3.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Windsor Private Capital Lp also recently made the following trade(s):

• On Thursday, October 16th, Windsor Private Capital Lp sold 40,139 shares of Firefly Neuroscience stock. The shares were sold at an average price of $2.65, for a total transaction of $106,368.35.
• On Wednesday, October 15th, Windsor Private Capital Lp sold 17,500 shares of Firefly Neuroscience stock. The shares were sold at an average price of $2.74, for a total transaction of $47,950.00.
• On Tuesday, October 14th, Windsor Private Capital Lp sold 29,500 shares of Firefly Neuroscience stock. The shares were sold at an average price of $2.74, for a total transaction of $80,830.00.
• On Monday, October 13th, Windsor Private Capital Lp sold 32,136 shares of Firefly Neuroscience stock. The shares were sold at an average price of $2.65, for a total transaction of $85,160.40.
• On Friday, October 10th, Windsor Private Capital Lp sold 74,810 shares of Firefly Neuroscience stock. The shares were sold at an average price of $2.70, for a total transaction of $201,987.00.
• On Thursday, October 9th, Windsor Private Capital Lp sold 30,126 shares of Firefly Neuroscience stock. The shares were sold at an average price of $2.94, for a total transaction of $88,570.44.

Firefly Neuroscience Price Performance

Shares of NASDAQ AIFF opened at $2.51 on Monday. Firefly Neuroscience, Inc. has a 1 year low of $1.86 and a 1 year high of $17.20. The company’s 50-day moving average is $2.78 and its 200 day moving average is $2.97. The stock has a market capitalization of $33.76 million, a P/E ratio of -1.00 and a beta of 2.11.

Firefly Neuroscience (NASDAQ:AIFF) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter. Firefly Neuroscience had a negative net margin of 5,335.75% and a negative return on equity of 464.02%.

Institutional Investors Weigh In On Firefly Neuroscience

An institutional investor recently raised its position in Firefly Neuroscience stock. Geode Capital Management LLC increased its holdings in shares of Firefly Neuroscience, Inc. (NASDAQ:AIFF) by 92.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120,604 shares of the company’s stock after acquiring an additional 58,067 shares during the period. Geode Capital Management LLC owned approximately 0.94% of Firefly Neuroscience worth $341,000 at the end of the most recent reporting period. Institutional investors own 4.96% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Firefly Neuroscience in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Firefly Neuroscience Company Profile

Firefly Neuroscience, Inc, a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder.